Larazotide Acetate or INN-202 is Innovate's leading drug candidate for Celiac Disease (CeD) entering phase 3 clinical trials. INN-202 is a tight junction regulator, which helps restore “leaky” or open junctions to a normal state. In CeD patients, ingestion of gluten causes disruption or opening of the tight junctions. The open junctions cause an inflammatory cascade within the intestinal epithelium that eventually destroys the intestinal villi, decreasing the surface area for absorption of nutrients, thus leading to a variety of diseases. When ingested prior to a meal, Larazotide may help keep the tight junctions closed, thus reducing the intestinal-inflammatory process in response to gluten.
Intestinal permeability is thought be involved in a variety of GI and autoimmune diseases and using a safe, non-absorbed drug like Larazotide with more than 800 patient exposure, can allow for rapid proof-of-concept clinical trials.
Celiac Disease remains an unmet need with no drugs approved. Patients diagnosed with Celiac Disease only have the gluten-free diet to manage their symptoms. There are more than 3 million Celiac patients in the US and a similar number in Europe with another 15 million in the rest of the world.Larazotide would be the first drug ever approved for Celiac Disease by 2018.
Larazotide is the only late-stage drug entering phase 3 trials with a path forward agreed upon with the FDA. After several clinical trials involving more than 800 patients and a phase 2b trial with 342 patients, Larazotide has been shown to be safe and effective in a “real world setting” for Celiac patients. Phase 3 trials are expected to begin later in 2017.